RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-7.01%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$880M
AUM Growth
+$880M
(-13%)
Cap. Flow
-$43.3M
Cap. Flow
% of AUM
-4.92%
Top 10 Holdings %
Top 10 Hldgs %
31.67%
Holding
96
New
7
Increased
26
Reduced
40
Closed
10
Top Buys
| 1 |
Abbott
ABT
|
$8.69M |
| 2 |
Boston Scientific
BSX
|
$8.01M |
| 3 |
Humana
HUM
|
$7.72M |
| 4 |
Thermo Fisher Scientific
TMO
|
$7.25M |
| 5 |
Royalty Pharma
RPRX
|
$6.31M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$16.1M |
| 2 |
Centene
CNC
|
$15.7M |
| 3 |
Eli Lilly
LLY
|
$10.9M |
| 4 |
McKesson
MCK
|
$10.4M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$8.57M |
Sector Composition
| 1 | Healthcare | 98.45% |
| 2 | Industrials | 0.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioNTech
BNTX
$24.1B
| $13.4M | 1.52% |
90,000
+5,000
| +6% | +$746K |
|
|
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $12.8M | 1.45% |
190,000
+40,200
| +27% | +$2.7M |
|
28
Harmony Biosciences
HRMY
$2.16B
| $12.7M | 1.44% |
260,000
-8,244
| -3% | -$402K |
|
29
Gilead Sciences
GILD
$140B
| $12.4M | 1.4% |
200,000
+30,000
| +18% | +$1.85M |
|
30
BioMarin Pharmaceuticals
BMRN
$11.3B
| $11.6M | 1.32% |
140,000
-80,000
| -36% | -$6.63M |
|
31
Cooper Companies
COO
$13.3B
| $11.6M | 1.32% |
148,000
-36,000
| -20% | -$2.82M |
|
32
Becton Dickinson
BDX
$54.3B
| $11.1M | 1.26% |
45,000
-613
| -1% | -$151K |
|
33
Alnylam Pharmaceuticals
ALNY
$58.6B
| $10.9M | 1.24% |
75,000
-55,000
| -42% | -$8.02M |
|
34
Dynavax Technologies
DVAX
$1.19B
| $10.1M | 1.14% |
800,000
+119,324
| +18% | +$1.5M |
|
35
Apellis Pharmaceuticals
APLS
$3.51B
| $9.5M | 1.08% |
210,000
-167,000
| -44% | -$7.55M |
|
36
Neurocrine Biosciences
NBIX
$13.5B
| $9.26M | 1.05% |
95,000
-10,000
| -10% | -$975K |
|
37
Inspire Medical Systems
INSP
$2.53B
| $9.13M | 1.04% |
50,000
+2,500
| +5% | +$457K |
|
38
Cytokinetics
CYTK
$5.98B
| $9.04M | 1.03% |
230,000
-65,000
| -22% | -$2.55M |
|
39
Privia Health
PRVA
$2.85B
| $8.74M | 0.99% |
300,000
-97,510
| -25% | -$2.84M |
|
|
40
Regeneron Pharmaceuticals
REGN
$59.8B
| $8.28M | 0.94% |
14,000
-14,500
| -51% | -$8.57M |
|
41
Xencor
XNCR
$594M
| $8.21M | 0.93% |
300,000
-43,636
| -13% | -$1.19M |
|
|
SGEN
42
DELISTED
Seagen Inc. Common Stock
SGEN
| $8M | 0.91% |
45,208
-15,792
| -26% | -$2.79M |
|
|
ITCI
43
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.99M | 0.91% |
140,000
-140,000
| -50% | -$7.99M |
|
44
Veeva Systems
VEEV
$44.4B
| $7.53M | 0.86% |
38,000
| – | – |
|
|
RCM
45
DELISTED
R1 RCM Inc. Common Stock
RCM
| $6.81M | 0.77% |
325,000
+42,811
| +15% | +$897K |
|
|
SILK
46
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $6.37M | 0.72% |
175,000
+25,000
| +17% | +$910K |
|
|
47
Royalty Pharma
RPRX
$15.8B
| $6.31M | 0.72% |
+150,000
| New | +$6.31M |
|
|
RVNC
48
DELISTED
Revance Therapeutics, Inc.
RVNC
| $6.22M | 0.71% |
450,000
+251,642
| +127% | +$3.48M |
|
49
Iovance Biotherapeutics
IOVA
$800M
| $5.85M | 0.66% |
530,000
+55,000
| +12% | +$607K |
|
50
Esperion Therapeutics
ESPR
$490M
| $5.72M | 0.65% |
900,000
-81,582
| -8% | -$519K |
|